Efficacy and maintenance of rituximab treatment in non‐infectious scleritis.

The patients who received RTX later than one year after the onset of scleritis exhibited recurrences and/or failure of RTX treatment more often (p = 0.03). Scleritis is characterized by intense pain, redness, potentially destructive complications, and frequently insufficient response to local and systemic treatments (Sainz de la Maza et al. 2012; Wieringa et al. 2013). Rituximab (RTX) was introduced as treatment for scleritis after its successful use for systemic autoimmune diseases associated with scleritis. [Extracted from the article]